GlassScriptPhysician profile
Cindi S Boderman
NPI 1164968608
$4,520.54
in general payments reported to CMS, 2019-2025
21 companies · $2,085 in 2025
The $2,085 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $17.06 · 2024: $2,419 · 2025: $2,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,422 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,421.54 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,025.96 | 2024-2025 | |
| Janssen Biotech, INC. | $813.15 | 2024-2025 | Tremfya, Simponi Aria, Remicade |
| Novartis Pharmaceuticals Corporation | $499.49 | 2024-2025 | |
| Amgen INC. | $399.74 | 2024-2025 | Enbrel, Otezla, Tavneos |
| Lilly USA, LLC | $304.44 | 2024-2025 | Taltz, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $245.24 | 2024-2025 | Orencia |
| Ucb, INC. | $225.47 | 2023-2025 | Bimzelx, Cimzia |
| Mallinckrodt Hospital Products INC. | $198.50 | 2025 | Acthar |
| Ani Pharmaceuticals, INC. | $129.99 | 2024-2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $95.70 | 2024-2025 | Benlysta |
| Genentech USA, INC. | $92.97 | 2024-2025 | Actemra, Gazyva |
| Alexion Pharmaceuticals, INC. | $72.67 | 2024 | Strensiq |
| Pfizer INC. | $71.64 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $68.19 | 2025 | Lupkynis |
| Radius Health, INC. | $62.14 | 2025 | Tymlos |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $48.06 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $45.66 | 2024 | Opsumit, Uptravi |
| Organon LLC | $40.16 | 2024 | |
| Sandoz INC. | $36.25 | 2024 | Hyrimoz |
| Tersera Therapeutics LLC | $24.30 | 2025 | Quzyttir |
| Astrazeneca Pharmaceuticals LP | $20.82 | 2025 | Saphnelo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindi Boderman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.